Hemolytic Anemia: Drug Therapy

Therapeutic targets

  • Compensation of anemia
  • Cure (see below beta-thalassemia).

Therapy recommendations

  • Therapy for hemolytic anemia depends on the underlying disorder in each case.
  • In many cases, additional blood transfusions are needed.
  • See also under “Further therapy“.

Therapy an acute hemolytic crisis in the context of a transfusion incident (mistransfusion in the AB0 system):

  • Immediate stop of the transfusion
  • Symptomatic therapy: volume substitution, administration of glucocorticoids, and urinary alkalinization with sodium bicarbonate
  • Ultima Ratio: exchange transfusion.

Therapy of hereditary hemolytic anemia/red cell membrane defects:

  • In addition to the recommended splenectomy (surgical removal of the spleen), prophylaxis with folic acid should also be performed in cases of severe hemolysis. → the daily requirement is then about 300-400 μg; In manifest folic acid deficiency should be added 5-15 mg/d.
  • Before splenectomy, vaccination against pneumococcus and H. influenzae should be performed.

Therapy of autoimmune hemolytic anemia by heat antibodies:

Therapy of thalassemia (disorders of hemoglobin formation).

  • To date, cure by allogeneic stem cell therapy.
  • Gene therapy for beta-thalassemia; the patient’s stem cells are taken and given a correct version of the gene using lentiviruses in the laboratory before infusion.In a phase II study, 3 of 9 patients were able to completely avoid blood transfusions after gene therapy; the others had a significant reduction in transfusions (by 73% in the entire group). Since patients’ therapies now range from 15 to 42 months, the chances of cure are good.